Efficacy and safety of upadacitinib through 140 weeks in Chinese adult and adolescent patients with moderate-to-severe atopic dermatitis: Post hoc analysis of the phase 3 Measure Up 1 and AD Up clinical trials.

COI Statement

AbbVie funded the research for this study. Michael Lane, Andrew Platt, Shereen Hammad and Qichen Fan are full-time employees of AbbVie and may hold stock or stock options.

References:

• Guttman-Yassky E Teixeira HD Simpson EL Papp KA Pangan AL Blauvelt A, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): Results from two replicate double-blind, randomised controlled phase 3 trials. Lancet 2021;397:2151–2168. doi: 10.1016/S0140-6736(21)00588-2.
• Reich K Teixeira HD de Bruin-Weller M Bieber T Soong W Kabashima K, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): Results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2021;397:2169–2181. doi: 10.1016/S0140-6736(21)00589-4.
• Silverberg JI Gooderham MJ Paller AS Deleuran M Bunick CG Gold LFS, et al. Early and sustained improvements in symptoms and quality of life with upadacitinib in adults and adolescents with moderate-to-severe atopic dermatitis: 52-week results from two phase III randomized clinical trials (Measure Up 1 and Measure Up 2). Am J Clin Dermatol 2024;25:485–496. doi: 10.1007/s40257-024-00853-4.
• Silverberg JI de Bruin-Weller M Bieber T Soong W Kabashima K Costanzo A, et al. Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results. J Allergy Clin Immunol 2022;149:977–987.e14. doi: 10.1016/j.jaci.2021.07.036.
• Suaini NHA, Tan CPT, Loo EXL, Tham EH. Global differences in atopic dermatitis. Pediatr Allergy Immunol 2021;32:23–33. doi: 10.1111/pai.13335.